Previous close | 0.2120 |
Open | 0.2140 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.2140 - 0.2140 |
52-week range | 0.0950 - 0.2440 |
Volume | |
Avg. volume | 0 |
Market cap | 156.785M |
Beta (5Y monthly) | 0.99 |
PE ratio (TTM) | ∞ |
EPS (TTM) | 0.0000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 04 May 2023 |
1y target est | N/A |
Drugmakers are in a race to develop vaccines and drugs to treat respiratory diseases caused by respiratory syncytial virus and COVID-19, resulting in increased demand for clinical testing of the products. The contract research organisation now expects its annual revenue to be 55 million pounds ($68.8 million), compared with 53 million pounds it previously expected.